EP2991687A4 - Prosthetic compounds for labeling internalizing biomolecules - Google Patents

Prosthetic compounds for labeling internalizing biomolecules

Info

Publication number
EP2991687A4
EP2991687A4 EP14792079.7A EP14792079A EP2991687A4 EP 2991687 A4 EP2991687 A4 EP 2991687A4 EP 14792079 A EP14792079 A EP 14792079A EP 2991687 A4 EP2991687 A4 EP 2991687A4
Authority
EP
European Patent Office
Prior art keywords
biomolecules
internalizing
labeling
prosthetic compounds
prosthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14792079.7A
Other languages
German (de)
French (fr)
Other versions
EP2991687A1 (en
Inventor
Michael Zalutsky
Ganesan Vaidyanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP2991687A1 publication Critical patent/EP2991687A1/en
Publication of EP2991687A4 publication Critical patent/EP2991687A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14792079.7A 2013-05-02 2014-05-02 Prosthetic compounds for labeling internalizing biomolecules Ceased EP2991687A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818722P 2013-05-02 2013-05-02
PCT/US2014/036615 WO2014179715A1 (en) 2013-05-02 2014-05-02 Prosthetic compounds for labeling internalizing biomolecules

Publications (2)

Publication Number Publication Date
EP2991687A1 EP2991687A1 (en) 2016-03-09
EP2991687A4 true EP2991687A4 (en) 2016-11-09

Family

ID=51843983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14792079.7A Ceased EP2991687A4 (en) 2013-05-02 2014-05-02 Prosthetic compounds for labeling internalizing biomolecules

Country Status (3)

Country Link
US (1) US9839704B2 (en)
EP (1) EP2991687A4 (en)
WO (1) WO2014179715A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178936A1 (en) * 2017-03-30 2018-10-04 Duke University Radiolabeled biomolecules and their use
EP3630286A4 (en) 2017-05-30 2021-03-03 RefleXion Medical, Inc. Methods for real-time image guided radiation therapy
JP2020525093A (en) * 2017-06-22 2020-08-27 リフレクション メディカル， インコーポレイテッド Systems and methods for biocompatible radiation therapy
WO2020150505A1 (en) 2019-01-16 2020-07-23 Reflexion Medical, Inc. Methods for setup corrections in radiation therapy
US20220226513A1 (en) 2019-05-24 2022-07-21 Duke University 18f-radiolabeled biomolecules
CA3146431A1 (en) 2019-07-12 2021-01-21 Reflexion Medical, Inc. Multi-target treatment planning and delivery and virtual localization for radiation therapy
EP4058423A1 (en) 2019-11-13 2022-09-21 Duke University Radiohalogen prosthetic moieties and radiolabeled biomolecules
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031333A1 (en) * 2003-01-02 2007-02-08 Mease Ronnie C Novel F-18 labeled annexin V, synthesis thereof, and use thereof
WO2009080561A1 (en) * 2007-12-20 2009-07-02 General Electric Company Selective radiolabeling of biomolecules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2452695A3 (en) * 2004-12-23 2013-01-23 Purdue Research Foundation Positron emission tomography imaging method
EP2334642B1 (en) 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
JP2014076949A (en) 2011-02-09 2014-05-01 Kyoto Univ Production method of radioactively labeled polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031333A1 (en) * 2003-01-02 2007-02-08 Mease Ronnie C Novel F-18 labeled annexin V, synthesis thereof, and use thereof
WO2009080561A1 (en) * 2007-12-20 2009-07-02 General Electric Company Selective radiolabeling of biomolecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014179715A1 *
SHUANGLONG LIU ET AL: "Lewis Acid-Assisted Isotopic 18 F- 19 F Exchange in BODIPY Dyes: Facile Generation of Positron Emission Tomography/Fluorescence Dual Modality Agents for Tumor Imaging", THERANOSTICS, vol. 3, no. 3, 1 January 2013 (2013-01-01), AU, pages 181 - 189, XP055306708, ISSN: 1838-7640, DOI: 10.7150/thno.5984 *

Also Published As

Publication number Publication date
WO2014179715A1 (en) 2014-11-06
EP2991687A1 (en) 2016-03-09
US20160074541A1 (en) 2016-03-17
US9839704B2 (en) 2017-12-12

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti-fcrh5 antibodies
HK1224241A1 (en) Container for filter-as-you-pour system
GB201322583D0 (en) Antibodies
HK1220142A1 (en) Antibodies
GB201308658D0 (en) Antibodies
EP2991687A4 (en) Prosthetic compounds for labeling internalizing biomolecules
GB201315486D0 (en) Antibodies
PT3026417T (en) Container for specimen preparation
GB201801587D0 (en) Marker Development
HRP20190085T1 (en) Anti-cd52 antibodies
IL245488A0 (en) Anti-ccl17 antibodies
GB201318283D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 51/02 20060101ALI20161004BHEP

Ipc: A61K 49/10 20060101ALI20161004BHEP

Ipc: A61K 51/04 20060101AFI20161004BHEP

Ipc: A61K 49/04 20060101ALI20161004BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180220

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190627